[ad_1]
Johnson & Johnson’s subsidiary, Janssen-Cilag, applied for the vector-based vaccine almost simultaneously in Europe and Canada, as the pharmaceutical authority Swissmedic announced on Monday.
The vaccine was developed at the Janssen Vaccine Laboratory in Bern-Bümpliz, among others. Johnson & Johnson had already developed an Ebola vaccine at the Bern site in a rapid process. This was created using a new process. This is now also used for the development of the corona vaccine.
Can be stored at 2 degrees
Like AstraZeneca’s, Bern’s new vaccine will be based on an adenovirus that also occurs in nature. US Moderna’s corona vaccine, on the other hand, which is also produced at Lonza in Visp VS, and that from Biontech / Pfizer are based on new mRNA technology. The latter is going to vaccinate the elderly for the first time in Britain on Tuesday.
The difficulty of the first corona vaccine to hit the market is the low storage temperature of -75 degrees. Janssen corona vaccine, on the other hand, can be stored and transported at 2 to 8 degrees.
According to Dirk Redlich (52), Head of Vaccine Technical Development at Janssen Worldwide, the Bern location is “Janssen Vaccines’ Swiss Army Knife” worldwide, as he told VIEW. (gnc)
